Format

Send to

Choose Destination
Dev Med Child Neurol. 2017 Apr;59(4):441-444. doi: 10.1111/dmcn.13362. Epub 2016 Dec 9.

Tolerability and efficacy of perampanel in children with refractory epilepsy.

Author information

1
Department of Pediatric Neurology, Assaf Harofeh Medical Center, Zerifin, Israel.
2
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
3
Clinical Pharmacology Unit, Assaf Harofeh Medical Center, Zerifin, Israel.
4
Electroencephalography Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel.

Abstract

AIM:

There are few reports on the tolerability and efficacy of perampanel, a new antiepileptic drug with a novel mechanism of action, in children and adolescents. We aimed to describe our experience with perampanel add-on and mono-therapy in children with refractory epilepsy.

METHOD:

Computerized medical records of children treated with perampanel in the paediatric neurology clinic from December 2012 to October 2015 were reviewed.

RESULTS:

Twenty-four children treated with perampanel (15 females, 9 males) aged 1 year 6 months to 17 years (mean 10y, standard deviation [SD] 4y 5mo) were identified. Adverse events were more common in children aged 12 years or older (89%) compared to younger children (53%), and were mainly behavioural. Ten (42%) children had 50 per cent or higher seizure reduction, two (8%) children had 33 per cent seizure reduction, and seizures were less severe in one (4%) child. Perampanel was discontinued in 13 (54%) children mostly due to adverse events. The mean duration of follow-up in the remaining 11 children was 8.1 months (SD 5.2) (range 1.3-17mo).

INTERPRETATION:

Perampanel is associated with a relatively high rate of behavioural adverse events mostly in adolescents with refractory epilepsy.

PMID:
27935018
DOI:
10.1111/dmcn.13362
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center